Founded in 2001 and based on the work of Dr Peter Evans and Dr Nathan Griffiths, Abcellute is a product led company which exploits a patent protected cell stabilising platform technology which enables the non-frozen preservation and transport of live organ-derived cells without the loss of viability or function. The Abcellute product is currently being sold to pharmaceutical companies in the UK for pre-clinical drug testing and the company is actively expanding these sales to Asia and the USA. In the long-term, the company plans to develop the preservation technology to provide products for cell-based therapeutics.